ESC 2022 Cardio-Oncology Guidelines: Paving the way for cardiovascular care through the minefield of cardiotoxicity in cancer survivorship
|Take Home Messages|
Cardiovascular disease (CVD) and cancer are two major causes of mortality worldwide (1). Chemotherapeutic agents have come a long way and the advent of targeted therapies has ushered in a new era of personalised cancer care which, along with risk factor reduction, have shown a decline in cancer mortality (2, 3). As cancer survival improves, the burden of CVD becomes more apparent (4). The Surveillance, Epidemiology and End Results (SEER) database showed that the risk of mortality from CVD was greatest in the first year of cancer diagnosis and patients diagnosed under 55 years old had a ten-fold risk of CVD related death compared to the general population (5).